MY128529A - Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure - Google Patents

Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Info

Publication number
MY128529A
MY128529A MYPI20032768A MYPI20032768A MY128529A MY 128529 A MY128529 A MY 128529A MY PI20032768 A MYPI20032768 A MY PI20032768A MY PI20032768 A MYPI20032768 A MY PI20032768A MY 128529 A MY128529 A MY 128529A
Authority
MY
Malaysia
Prior art keywords
prevention
treatment
pharmaceutically acceptable
heart failure
cilobradine
Prior art date
Application number
MYPI20032768A
Other languages
English (en)
Inventor
Brian Dr Guth
Randolph Dr Seidler
Juergen Dr Daemmgen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY128529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY128529A publication Critical patent/MY128529A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20032768A 2002-07-25 2003-07-23 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure MY128529A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
MY128529A true MY128529A (en) 2007-02-28

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20032768A MY128529A (en) 2002-07-25 2003-07-23 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Country Status (29)

Country Link
US (1) US20130317008A1 (enExample)
EP (2) EP1362590B1 (enExample)
JP (3) JP2005533853A (enExample)
KR (1) KR20050074432A (enExample)
CN (1) CN100502874C (enExample)
AR (1) AR040690A1 (enExample)
AT (2) ATE257384T1 (enExample)
AU (1) AU2003254554B8 (enExample)
BR (1) BR0312852A (enExample)
CA (1) CA2493208C (enExample)
CO (1) CO5700723A2 (enExample)
CY (1) CY1112173T1 (enExample)
DE (1) DE60200160T2 (enExample)
DK (2) DK1362590T3 (enExample)
ES (2) ES2211846T3 (enExample)
HR (1) HRP20050075B1 (enExample)
MX (1) MXPA05000617A (enExample)
MY (1) MY128529A (enExample)
NZ (1) NZ538424A (enExample)
PE (1) PE20040706A1 (enExample)
PL (1) PL214716B1 (enExample)
PT (2) PT1362590E (enExample)
SA (1) SA03240350B1 (enExample)
SI (2) SI1362590T1 (enExample)
TR (1) TR200400127T4 (enExample)
TW (1) TWI319321B (enExample)
UY (1) UY27910A1 (enExample)
WO (1) WO2004011006A1 (enExample)
ZA (1) ZA200500084B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP2741735A1 (en) 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
PT1186601E (pt) * 1999-06-03 2004-06-30 Yamanouchi Pharma Co Ltd Novos derivados de isoquinolina ou seus sais
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Also Published As

Publication number Publication date
AU2003254554A1 (en) 2004-02-16
AR040690A1 (es) 2005-04-13
CN100502874C (zh) 2009-06-24
TWI319321B (en) 2010-01-11
MXPA05000617A (es) 2005-08-19
TR200400127T4 (tr) 2004-02-23
PT1362590E (pt) 2004-05-31
DK1362590T3 (da) 2004-03-29
ES2211846T3 (es) 2004-07-16
TW200412974A (en) 2004-08-01
ATE257384T1 (de) 2004-01-15
JP2005533853A (ja) 2005-11-10
EP1362590A8 (en) 2004-02-25
ES2367109T3 (es) 2011-10-28
CO5700723A2 (es) 2006-11-30
PL214716B1 (pl) 2013-09-30
AU2003254554B8 (en) 2009-02-26
CY1112173T1 (el) 2015-12-09
CN1671392A (zh) 2005-09-21
ATE510543T1 (de) 2011-06-15
BR0312852A (pt) 2005-04-19
UY27910A1 (es) 2004-02-27
PL372993A1 (en) 2005-08-08
JP2009256379A (ja) 2009-11-05
SA03240350B1 (ar) 2007-10-29
DE60200160D1 (de) 2004-02-12
CA2493208A1 (en) 2004-02-05
AU2003254554B2 (en) 2009-01-29
HRP20050075A2 (en) 2005-12-31
SI1362590T1 (sl) 2004-04-30
PT1534296E (pt) 2011-08-18
HRP20050075B1 (hr) 2013-12-20
CA2493208C (en) 2011-11-01
WO2004011006A1 (en) 2004-02-05
EP1534296A1 (en) 2005-06-01
NZ538424A (en) 2006-10-27
DE60200160T2 (de) 2004-11-04
PE20040706A1 (es) 2004-12-06
SI1534296T1 (sl) 2011-09-30
EP1534296B1 (en) 2011-05-25
ZA200500084B (en) 2005-10-26
KR20050074432A (ko) 2005-07-18
JP2013166781A (ja) 2013-08-29
DK1534296T3 (da) 2011-08-15
US20130317008A1 (en) 2013-11-28
EP1362590A1 (en) 2003-11-19
EP1362590B1 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
GEP20074047B (en) Pramipexole once-daily dosage form
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
MXPA03010761A (es) Combinaciones farmaceuticas.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
ATE491709T1 (de) Pyrrolidinohydrochinazoline
LT2004049A (en) Citalopram for the treatment of elevated blood pressure
BG106428A (en) Pharmaceutical compositions for treating psoriasis
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.